Market closedNon-fractional
Revance Therapeutics/RVNC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Revance Therapeutics
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Ticker
RVNC
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Nashville, United States
Employees
597
Website
www.revance.com
RVNC Metrics
BasicAdvanced
$393M
Market cap
-
P/E ratio
-$3.64
EPS
1.05
Beta
-
Dividend rate
Price and volume
Market cap
$393M
Beta
1.05
Financial strength
Current ratio
5.365
Quick ratio
4.455
Long term debt to equity
-469.886
Total debt to equity
-482.175
Interest coverage (TTM)
-10.98%
Management effectiveness
Return on assets (TTM)
-26.14%
Return on equity (TTM)
518.63%
Valuation
Price to revenue (TTM)
1.366
Price to book
-4
Price to tangible book (TTM)
-3.67
Price to free cash flow (TTM)
-1.487
Growth
Revenue change (TTM)
56.91%
Earnings per share change (TTM)
-21.56%
3-year revenue growth (CAGR)
103.35%
3-year earnings per share growth (CAGR)
-8.64%
What the Analysts think about RVNC
Analyst Ratings
Majority rating from 12 analysts.
RVNC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$52M
-25.54%
Net income
-$53M
-4.50%
Profit margin
-102.31%
28.26%
RVNC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.80
-$1.63
-$0.62
-$0.58
-
Expected
-$0.78
-$0.85
-$0.72
-$0.75
-$0.53
Surprise
2.86%
91.09%
-14.38%
-22.67%
-
RVNC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Revance Therapeutics stock?
Revance Therapeutics (RVNC) has a market cap of $393M as of July 27, 2024.
What is the P/E ratio for Revance Therapeutics stock?
The price to earnings (P/E) ratio for Revance Therapeutics (RVNC) stock is 0 as of July 27, 2024.
Does Revance Therapeutics stock pay dividends?
No, Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Revance Therapeutics dividend payment date?
Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders.
What is the beta indicator for Revance Therapeutics?
Revance Therapeutics (RVNC) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Revance Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.